-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
August 16, 2020 // -- In-depth revelations about cellular signals that control cancer growth and migration may help in the search for effective anti-cancer drugs, scientists from Institutions such as McGill University have found or can help understand key biogenic processes of the pathogenesis of colorectal cancer in a recent study published in the international journal Journal of Biological Chemistry. In the
paper, the researchers analyzed the behavior of key enzymes involved in the spread of cancer cells, noting that there may be a more refined interaction between an enzyme called PRL3 and another protein that moves magnesium ions inside and outside the cell, which is essential for the growth of colorectal cancer.
image source: Unsplash/CC0 Public Domain researcher Dr Kalle Gehring says these enzymes first appear in liver cells that are activated to open up cell growth, so they may be able to act as growth signals; In this study, researchers found that the second activity of prL3 enzyme, the control of magnesium ion transport proteins, which guide the spread of cancer cells in other parts of the body, does not appear to catalytic activity, but binds closely to magnesium ion transport proteins and is as carcinogenic as wild proteins.
The study raises long-standing questions about scientists' long-held hypothesis that PRL3 plays a key role in cancer diffusion, and the researchers believe that special binding mechanisms may be key to some extent; understanding the mechanisms by which binding to magnesium ion transport proteins, rather than the catalytic activity of enzymes, affects cancer growth and migration signals may hopefully help researchers identify new compounds to prevent cancer from spreading.
Current drug screening for PRL3 focuses on finding compounds that block phosphatase activity, and by detecting the wrong function, this screening may miss out on other compounds that may have therapeutic potential, shifting the focus to enzyme activity that binds magnesium ion transport proteins may help many pharmaceutical companies better identify new cancer therapies through drug screening methods.
later this year, researchers will continue to conduct more in-depth studies to analyze the key role magnesium ion transport proteins play in the spread of cancer and how they interact with PRL3.
original source: Guennadi Kozlov et al, PRL3 pseudophosphatase activity is necessary and to promote metastatic growth, Journal of Biological Chemistry (2020). doi:10.1074/jbc. RA120.014464.